Heart Pill for Obstructive HCM from About 66 Pounds
Camzyos (mavacamten) — oral treatment for symptomatic obstructive HCM from about 66 lb
This is for families living with symptomatic obstructive hypertrophic cardiomyopathy when the person weighs at least 30 kg (about 66 lb). It explains the US prescribing-information expansion that added eligible pediatric patients to Camzyos (mavacamten), the REMS and echo path, and what SCOUT-HCM showed on the outflow gradient. It is not approved under 30 kg, not a local-pharmacy fill, and not an approval outside the United States for this pediatric wording on sources checked here. Authorized is not funded.
The FDA and Health Canada have labelled an oral HER2 tyrosine-kinase inhibitor for adults with locally advanced or metastatic NSCLC whose tumours have HER2 (ERBB2) tyrosine kinase domain activating…
Monthly Shot to Lower Triglycerides and Pancreatitis Risk
Tryngolza (olezarsen) — ApoC-III ASO for severe hypertriglyceridemia (sHTG) and FCS
This is for adults with severe hypertriglyceridemia (fasting TG 500 mg/dL or higher) — and caregivers — who need a labelled way to lower triglycerides and cut the risk of acute pancreatitis, and for…
Once-Daily Pill for FOP Bone Growth in Teens and Adults
Atebrioz (zilurgisertib) — oral ALK2 inhibitor to reduce new heterotopic ossification in FOP (ages 12+)
This is for teens 12 and older and adults with fibrodysplasia ossificans progressiva (FOP) — and caregivers — who need a labelled way to slow new extra bone (heterotopic ossification).
Breakthrough Brief
New treatments and trials, weekly. Every email has an unsubscribe link.
By subscribing, you request Breakthrough Brief emails. Privacy
Special series
Breaking Out: The Weight Class — Shots, Pills, and Organ Labels in 2026
Shots, pills, and organ labels in the 2026 weight class — Wegovy injection, Zepbound, the oral maze, and the process line that authorized is not funded. International by default. Zoom by country. Authorized is not funded.
This is for adults with previously treated unresectable, locally advanced, or metastatic bile duct cancer (cholangiocarcinoma) that harbors an FGFR2 gene fusion or other rearrangement — and the…
Once-Weekly Basal Insulin Shot for Adults with Type 2 Diabetes
Onswik (insulin efsitora alfa-gobe) — once-weekly basal insulin for adults with type 2 diabetes
This is for adults with type 2 diabetes — and caregivers helping them — who may be candidates for a once-weekly basal insulin instead of a daily basal shot.
First EU Medicine for Early Brain ALD in Boys Ages 2–12
Nezglyal (leriglitazone) — oral suspension for early cerebral adrenoleukodystrophy (Gd-negative)
This is for boys aged 2 to 12 with early cerebral adrenoleukodystrophy (cALD) — Gd-negative brain lesions on MRI and a Neurological Functional Score of 0 or 1 — and the caregivers helping them.
New Prescription Ointment for Mild-to-Moderate Eczema Ages 2 and Up
Adquey (difamilast) — topical ointment for mild-to-moderate eczema (atopic dermatitis)
This is for people with mild to moderate atopic dermatitis (eczema) — and caregivers of children 2 years and older — who may be candidates for labelled US Adquey ointment.
First FDA-Approved Treatment for MCT8 Peripheral Thyrotoxicosis
Emcitate (tiratricol) — dispersible tablets for peripheral thyrotoxicosis in MCT8 deficiency
This is for people living with MCT8 deficiency (Allan-Herndon-Dudley syndrome) — and the caregivers who help them — who need an honest path to tiratricol.
This is for adults with superficial basal cell carcinoma — and the caregivers helping them — who may be candidates for labelled US Ameluz red-light PDT with a BF-RhodoLED or RhodoLED XL clinic lamp.
First FDA-Approved Implant Treatment for MacTel Eye Disease
Encelto (revakinagene taroretcel-lwey) — encapsulated cell implant for macular telangiectasia type 2
This is for adults living with idiopathic macular telangiectasia type 2 — and the caregivers who help them — who may be candidates for labelled US Encelto encapsulated cell implants at a…
First FDA-Approved Treatment for Ataxia in Ataxia-Telangiectasia
Aqneursa (levacetylleucine) — oral suspension for ataxia in ataxia-telangiectasia
This is for people living with ataxia-telangiectasia — and the caregivers who help them — who weigh at least 15 kg and may be candidates for labelled US Aqneursa oral suspension for ataxia.
This is for families of children (and adults) with genetically confirmed AADC deficiency from biallelic DDC changes who have achieved skull maturity and may be candidates for labelled US Kebilidi…